Fluorescent Indicators Distributed throughout the Pharmacophore of Cholecystokinin Provide Insights into Distinct Modes of Binding and Activation of Type A and B Cholecystokinin Receptors*
暂无分享,去创建一个
[1] L. Miller,et al. Use of N,O-bis-Fmoc-D-Tyr-ONSu for introduction of an oxidative iodination site into cholecystokinin family peptides. , 2009, International journal of peptide and protein research.
[2] L. Miller,et al. Differential Spatial Approximation between Cholecystokinin Residue 30 and Receptor Residues in Active and Inactive Conformations , 2005, Molecular Pharmacology.
[3] L. Miller,et al. Differential docking of high-affinity peptide ligands to type A and B cholecystokinin receptors demonstrated by photoaffinity labeling. , 2005, Biochemistry.
[4] A. Chakrabarti,et al. Effect of ionic strength on the organization and dynamics of tryptophan residues in erythroid spectrin: A fluorescence approach , 2005, Biopolymers.
[5] L. Miller,et al. Distinct Molecular Mechanisms for Agonist Peptide Binding to Types A and B Cholecystokinin Receptors Demonstrated Using Fluorescence Spectroscopy* , 2005, Journal of Biological Chemistry.
[6] L. Miller,et al. Key Differences in Molecular Complexes of the Cholecystokinin Receptor with Structurally Related Peptide Agonist, Partial Agonist, and Antagonist , 2004, Molecular Pharmacology.
[7] L. Miller,et al. Heterodimerization of Type A and B Cholecystokinin Receptors Enhance Signaling and Promote Cell Growth* , 2003, Journal of Biological Chemistry.
[8] A. Chakrabarti,et al. Organization and dynamics of tryptophan residues in erythroid spectrin: Novel structural features of denatured spectrin revealed by the wavelength‐selective fluorescence approach , 2003, Protein science : a publication of the Protein Society.
[9] A. D. Robertson,et al. Illuminating proteins with Aladan's lamp , 2002, Nature Structural Biology.
[10] Y. Jan,et al. Probing Protein Electrostatics with a Synthetic Fluorescent Amino Acid , 2002, Science.
[11] L. Miller,et al. Environment and Mobility of a Series of Fluorescent Reporters at the Amino Terminus of Structurally Related Peptide Agonists and Antagonists Bound to the Cholecystokinin Receptor* , 2002, The Journal of Biological Chemistry.
[12] T. Lybrand,et al. Refinement of the conformation of a critical region of charge-charge interaction between cholecystokinin and its receptor. , 2002, Molecular pharmacology.
[13] T. Lybrand,et al. Refinement of the Structure of the Ligand-occupied Cholecystokinin Receptor Using a Photolabile Amino-terminal Probe* , 2001, The Journal of Biological Chemistry.
[14] J. Rehfeld. Cholecystokinin and panic disorder — three unsettled questions , 2000, Regulatory Peptides.
[15] J. Crawley,et al. International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. , 1999, Pharmacological reviews.
[16] E. Kojro,et al. Direct identification of the agonist binding site in the human brain cholecystokininB receptor. , 1999, Biochemistry.
[17] J. Landers,et al. Structurally Related Peptide Agonist, Partial Agonist, and Antagonist Occupy a Similar Binding Pocket within the Cholecystokinin Receptor , 1999, The Journal of Biological Chemistry.
[18] T. Lybrand,et al. Direct Identification of a Second Distinct Site of Contact between Cholecystokinin and Its Receptor* , 1998, The Journal of Biological Chemistry.
[19] T. Lybrand,et al. Direct Identification of a Distinct Site of Interaction between the Carboxyl-terminal Residue of Cholecystokinin and the Type A Cholecystokinin Receptor Using Photoaffinity Labeling* , 1997, The Journal of Biological Chemistry.
[20] B. Maigret,et al. Identification of Two Amino Acids of the Human Cholecystokinin-A Receptor That Interact with the N-terminal Moiety of Cholecystokinin* , 1997, The Journal of Biological Chemistry.
[21] L. F. Kolakowski,et al. Identification of cholecystokinin-B/gastrin receptor domains that confer high gastrin affinity: utilization of a novel Xenopus laevis cholecystokinin receptor. , 1996, Molecular pharmacology.
[22] L. Miller,et al. Relationship Between Native and Recombinant Cholecystokinin Receptors: Role of Differential Glycosylation , 1996, Pancreas.
[23] S. Silvente-Poirot,et al. A Segment of Five Amino Acids in the Second Extracellular Loop of the Cholecystokinin-B Receptor Is Essential for Selectivity of the Peptide Agonist Gastrin* , 1996, The Journal of Biological Chemistry.
[24] August B. Smit,et al. Co-evolution of Ligand-Receptor Pairs in the Vasopressin/Oxytocin Superfamily of Bioactive Peptides (*) , 1996, The Journal of Biological Chemistry.
[25] L. F. Kolakowski,et al. The Role of the Cholecystokinin-B/Gastrin Receptor Transmembrane Domains in Determining Affinity for Subtype-selective Ligands(*) , 1995, The Journal of Biological Chemistry.
[26] R. Campbell,et al. Co-evolution of ligand-receptor pairs , 1994, Nature.
[27] R. Tsien,et al. A new generation of Ca2+ indicators with greatly improved fluorescence properties. , 1985, The Journal of biological chemistry.
[28] V. Mutt. Additional observations on cholecystokinin and the vasoactive intestinal polypeptide , 1981, Peptides.
[29] L. Miller,et al. Preparation and characterization of a probe for the cholecystokinin octapeptide receptor, N alpha (125I-desaminotyrosyl)CCK-8, and its interactions with pancreatic acini. , 1981, The Journal of biological chemistry.
[30] D Rodbard,et al. Ligand: a versatile computerized approach for characterization of ligand-binding systems. , 1980, Analytical biochemistry.
[31] G. Weber,et al. Synthesis and spectral properties of a hydrophobic fluorescent probe: 6-propionyl-2-(dimethylamino)naphthalene. , 1979, Biochemistry.
[32] Amitabha Chattopadhyay,et al. Exploring membrane organization and dynamics by the wavelength-selective fluorescence approach. , 2003, Chemistry and physics of lipids.
[33] M. Fournié-Zaluski,et al. [Enkephalin catabolism inhibitors and antalgics of the future: from preclinical research to clinical trials]. , 1999, Therapie.
[34] Kolakowski Lf. GCRDB: A G-PROTEIN-COUPLED RECEPTOR DATABASE , 1994 .